文献速递前列腺癌

预测磁共振检测到前列腺影像报告和数据系统/Likert评分≥3分病灶的患者中需活检检出临床显著前列腺癌:帝国快速前列腺影像与诊断风险评分的开发与多国外部验证

Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
PubMed 文献 · Eur Urol · 2022-08-11

基于多中心RAPID通路1189例因PSA升高和/或直肠指检异常转诊泌尿科的患者,开发并外部验证(六国2374例)帝国RAPID风险评分,用于预测MRI检测到PIRADS/Likert≥3分病灶中临床显著前列腺癌。五条目评分(年龄、PSA密度、既往阴性活检、前列腺体积、最高MRI评分)对Gleason≥3+4的校正c指数为0.82,外部验证0.80-0.86;在预测概率20%、30%、40%时分别可减少11%、21%、31%的活检,同时遗漏1.8%、6.2%、14%的临床显著前列腺癌。

要点

  • 五条目帝国RAPID风险评分预测Gleason≥3+4的校正c指数0.82,外部验证0.80-0.86。
  • 预测概率20%、30%、40%时分别减少11%、21%、31%活检,遗漏csPCa 1.8%、6.2%、14%。
  • 加入家族史、DRE和黑人种族的八条目评分提供相似结果。

核心结论

  • 帝国RAPID风险评分提供标准化工具,用于预测MRI检测到PIRADS/Likert≥3分病灶患者的临床显著前列腺癌,可支持前列腺活检决策。

研究设计与样本

  • 多中心RAPID通路纳入2017年4月27日至2019年10月25日因年龄特异性PSA升高和/或DRE异常转诊泌尿科的1189例患者。
  • 对MRI评分≥4或3分且PSA密度≥0.12 ng/ml/ml者行视觉配准或图像融合靶向及系统经会阴活检。
  • 采用多变量logistic回归分析14个变量,构建列线图并行决策曲线分析,在六国2374例患者中外部验证不同复杂度模型。

主要发现

  • 五条目帝国RAPID风险评分使用年龄、PSA密度、既往阴性活检、前列腺体积和最高MRI评分,预测Gleason≥3+4的校正c指数为0.82,外部验证0.80-0.86。
  • 纳入家族史、DRE和黑人种族的八条目帝国RAPID风险评分提供相似结果。
  • 决策曲线分析显示所有模型 superiority 相似,净获益差异在较高阈值概率时增大。

关键数值与推荐

  • 在预测Gleason≥3+4前列腺癌概率20%、30%、40%时,RAPID风险评分分别减少11%、21%、31%的活检,对应遗漏csPCa 1.8%、6.2%、14%(或放弃活检9.6%、17%、26%)。

临床怎么用

  • 帝国RAPID风险评分可用于MRI检测到PIRADS/Likert≥3分病灶患者,支持前列腺活检决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although multiparametric magnetic resonance imaging (MRI) has high sensitivity, its lower specificity leads to a high prevalence of false-positive lesions requiring biopsy. OBJECTIVE: To develop and externally validate a scoring system for MRI-detected Prostate Imaging Reporting and Data System (PIRADS)/Likert ≥3 lesions containing clinically significant prostate cancer (csPCa). DESIGN, SETTING, AND PARTICIPANTS: The multicentre Rapid Access to Prostate Imaging and Diagnosis (RAPID) pathway included 1189 patients referred to urology due to elevated age-specific prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE); April 27, 2017 to October 25, 2019. INTERVENTION: Visual-registration or image-fusion targeted and systematic transperineal biopsies for an MRI score of ≥4 or 3 + PSA density ≥0.12 ng/ml/ml. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Fourteen variables were used in multivariable logistic regression for Gleason ≥3 + 4 (primary) and Gleason ≥4 + 3, and PROMIS definition 1 (any ≥4 + 3 or ≥6 mm any grade; secondary). Nomograms were created and a decision curve analysis (DCA) was performed. Models with varying complexity were externally validated in 2374 patients from six international cohorts. RESULTS AND LIMITATIONS: The five-item Imperial RAPID risk score used age, PSA density, prior negative biopsy, prostate volume, and highest MRI score (corrected c-index for Gleason ≥3 + 4 of 0.82 and 0.80-0.86 externally). Incorporating family history, DRE, and Black ethnicity within the eight-item Imperial RAPID risk score provided similar outcomes. The DCA showed similar superiority of all models, with net benefit differences increasing in higher threshold probabilities. At 20%, 30%, and 40% of predicted Gleason ≥3 + 4 prostate cancer, the RAPID risk score was able to reduce, respectively, 11%, 21%, and 31% of biopsies against 1.8%, 6.2%, and 14% of missed csPCa (or 9.6%, 17%, and 26% of foregone biopsies, respectively). CONCLUSIONS: The Imperial RAPID risk score provides a standardised tool for the prediction of csPCa in patients with an MRI-detected PIRADS/Likert ≥3 lesion and can support the decision for prostate biopsy. PATIENT SUMMARY: In this multinational study, we developed a scoring system incorporating clinical and magnetic resonance imaging characteristics to predict which patients have prostate cancer requiring treatment and which patients can safely forego an invasive prostate biopsy. This model was validated in several other countries.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Peters M, Eldred-Evans D, Kurver P, et al. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. Eur Urol. 2022. PMID: 35963650. doi:10.1016/j.eururo.2022.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。